Mass STI treatment or pill after sex? major trial tests best bet for kenyan men
NCT ID NCT06468462
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests two strategies to control sexually transmitted infections (STIs) among 2,900 cisgender men who have sex with men in Kenya. One group gets a single dose of antibiotics every few months (WHO-recommended periodic presumptive treatment), another takes doxycycline within 72 hours after condomless sex (doxyPEP), and a third gets standard care. The goal is to see which approach best reduces new infections of gonorrhea, chlamydia, and syphilis over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cefixime, azithromycin, and doxycycline
- What this could lead to
- If successful, this could provide an effective, scalable strategy to reduce gonorrhea, chlamydia, and syphilis in high-risk men in resource-limited settings.
- What could go wrong
- This is a single open-label trial in Kenya, so results may not apply elsewhere. Antibiotic resistance is a concern, and the interventions may not be as effective in real-world conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHLAMYDIA (MALE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anza Mapema Clinic
RECRUITINGKisumu, Kenya
-
TRANSFORM Clinic
RECRUITINGNairobi, Kenya
-
University of Washington/Pwani Research Centre at the Ganjoni Municipal Clinic, Mombasa
RECRUITINGMombasa, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.